Focused On-demand Library for Zinc finger protein 526

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q8TF50

UPID:
ZN526_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8TF50; B3KV29; Q69YI2; Q96E24

BACKGROUND:
The Zinc finger protein 526, identified by the unique identifier Q8TF50, is implicated in the intricate process of transcriptional regulation. This protein's association with DNA suggests a pivotal role in controlling gene activity.

THERAPEUTIC SIGNIFICANCE:
Given its connection to Dentici-Novelli neurodevelopmental syndrome, characterized by severe intellectual and developmental impairments, exploring the functions of Zinc finger protein 526 could lead to groundbreaking treatments. Its regulatory role offers a promising pathway for developing interventions that could correct or ameliorate genetic dysfunctions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 595 of 8789